192 related articles for article (PubMed ID: 15583970)
1. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?
Manganelli P; Giuliani N; Fietta P; Mancini C; Lazzaretti M; Pollini A; Quaini F; Pedrazzoni M
Clin Rheumatol; 2005 Jun; 24(3):296-300. PubMed ID: 15583970
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system.
Fiore CE; Riccobene S; Mangiafico R; Santoro F; Pennisi P
Osteoporos Int; 2005 Dec; 16(12):2180-4. PubMed ID: 15983730
[TBL] [Abstract][Full Text] [Related]
3. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H
Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347
[TBL] [Abstract][Full Text] [Related]
4. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
[TBL] [Abstract][Full Text] [Related]
5. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
6. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
7. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
8. [New paradigms in the regulation of bone metabolism].
Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
[TBL] [Abstract][Full Text] [Related]
9. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
10. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
11. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
12. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
13. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
15. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
16. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
Stajszczyk M
Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
[No Abstract] [Full Text] [Related]
17. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
Maddi A; Hai H; Ong ST; Sharp L; Harris M; Meghji S
Bone; 2006 Aug; 39(2):283-8. PubMed ID: 16567138
[TBL] [Abstract][Full Text] [Related]
18. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
